212 results about "Antibiotics beta lactam" patented technology

Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.

The invention relates to targeted post translational modifi-cation of metallo-beta-lactamase by truncation and inser-tion of a dipeptide at the amino terminal end to reduce amino terminal heterogeneity in a recombinant DNA pro-duction system. A protein K-T-E-ΔBL is expressed, and modified by host proteases to E-ΔBL. Appropriate nucleotide molecules, vectors and hosts are also de-scribed. E-ΔBL is useful in a pharmaceutical composition for treating antibiotic induced adverse effects in the intes-tine of patients treated with beta-lactam antibiotics.

A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container.

A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I):In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of beta lactam antibiotics against many beta-lactamase producing bacteria.

Stabilized preparations which contain a beta-lactam antibiotic having an esterified carboxyl group attached directly to the mother nucleus, an oil and a phosphate.

The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects.

Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

The present invention relates to a process for the preparation of Meropenem of formula (I) in sterile form and also provides an improved process for the preparation of compound of formula (V), which is an important intermediate in the synthesis of Meropenem.

A pharmaceutical composition, comprising: at least one β-lactam antibiotic and at least one buffer component; wherein when the pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic mixed with the β-lactam antibiotic and the buffer component.

Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.

An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.

The invention relates to the technical field of medicines, in particular to a twin antibiotic compound formed by bonding each two parent nucleuses with the same structure of a beta-lactam antibiotic compound or of a derivative of the beta-lactam antibiotic compound with a dicarboxylic acid by two amido bonds, preparation method thereof and use thereof. The chemical structural general formula of the twin antibiotic compound is represented by a formula III. In the formula, R3 is a parent nucleus structure of a molecule of a penicillin compound or a derivative of the penicillin compound or a molecule of a cephalosporin compound or a derivative of the cephalosporin compound; and R may be alkyl and aryl or heteroaryl or substituted alkyl and substituted aryl or heteroaryl. In-vitro antibacterial experiments show that the beta-lactam twin antibiotic compound of the invention has remarkable antibacterial activity and is a novel antibacterial compound. The beta-lactam twin antibiotic compound of the invention can be used in the preparation of bacteriostats or bacteriacides as well as anti-infection medicaments. According to the general knowledge of pharmacy, the compound of the invention can be made into pharmaceutically acceptable salts or hydrates.

The invention discloses a method, a special kit and test paper strips for detecting beta-lactam antibiotics based on penicillin-binding protein. The receptor kit used for detecting beta-lactam antibiotics comprises: protein represented by SEQ ID NO: 1, enzyme labeled ampicillin and a standard substance solution, wherein the standard substance is penicillin G. The kit and colloidal gold test paper strips provided by the invention have advantages of high sensitivity, high accuracy, high precision, low cost, simple operation, short detection period, simple storage, and long shelf-life. The kit and colloidal gold test paper strips are suitable for various work units. With the kit and colloidal gold test paper strips, simultaneous and rapid detections of large batches of samples can be realized, and on-site high flux rapid detections can be realized. Therefore, the kit, the colloidal gold test paper strips and the method provided by the invention play an important role in the detections of beta-lactam antibiotics.

The invention discloses a kit test method of beta-lactam antibiotics residue in milk, comprising the following steps: performing once activation to bacillus stearothermophilus, then culturing the activated bacillus stearothermophilus in a production culture medium at 50-65 DEG C for 24-36h while stirring in a rotation speed of 100-150rpm, centrifugalizing to collect bacteria mire, adding agarose bromcresol purple solution, mixing evenly to ensure the number of spore in each kit reach 1.00*10<7>-2.50*10<8>cfu, subpackaging the spore in porous reaction vessels at 60-70 DEG C, covering aluminum-plastic film, placing upside down, sealing, placing the vessels in aluminum-plastic packages and storing in dark place while keeping from wet. The kit has the advantage of easy operation, high sensibility, good repeatability, low cost and high throughput, can be stored at 4-8 DEG C for 12-18 months and can be used to test beta-lactam antibiotics residue in milk.

Polymers (i.e. polyesters, polyamides, polythioesters, polyanhydrides, or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g., amoxicillin) and a beta-lactamase inhibitor (e.g., clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor (or a pharmaceutically acceptable salt thereof) to a host are also provided.

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

The invention provides a hapten comprising a 6-[D-alpha-aminoacetamido]penicillin derivative crosslinked at the alpha-amino group with a substituted or unsubstituted phenyldicarbaldehyde. In addition, the invention provides an immunogen comprising the aforementioned hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of an intact beta-lactam ring. The invention further provides a method and a kit for detecting, or determining the quantity of, beta-lactam antibiotics, as well as, use of the aforementioned conjugate with the aforementioned antibodies for detecting, or determining the quantity of, beta-lactam antibiotics. The present invention has broad specificity across the main first generation beta-lactams and can be used to test milk and meat and the like for the presence of residual beta-lactam antibiotics.

The invention relates to synergistic dihydroarteannuin oxyethylimidazole derivatives and application thereof. The dihydroarteannuin oxyethylimidazole derivatives have the structure disclosed as one of Formulae I-III, and can be used for preparing an antimicrobial synergist for antibiotics. The dihydroarteannuin derivatives can inhibit growth of multidrug-resistant Escherichia coli when being used independently or combined with beta-lactam antibiotics, reverse the drug resistance of the antibacterial drug to bacteria, and enhance the antimicrobial efficacy of antibiotics.

The invention discloses an application of a macrolide compound or a salt thereof and a pharmaceutical composition containing the macrolide compound or the salt, and provides a pharmaceutical composition. The pharmaceutical composition comprises one or more of a macrolide compound as shown in a formula 1 in the specification, a macrolide compound as shown in a formula 1' in the specification and pharmaceutically acceptable salts thereof, and beta-lactam antibiotics. One or more of the macrolide compound as shown in the formula 1, the macrolide compound as shown in the formula 1' and pharmaceutically acceptable salts thereof disclosed by the invention has/have the effects of improving the effects of beta-lactam antibiotics and inhibiting methicillin-resistant staphylococcus aureus (MRSA); the macrolide compound is a novel synergist, is good in in-vitro synergism, is capable of relieving the drug resistance of the methicillin-resistant staphylococcus aureus (MRSA) on beta-lactam antibiotics, and is a medicine with good market development prospect.

Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.